Vosslamber S - Search Results

1

A multi-parameter response prediction model for rituximab in rheumatoid arthritis.

de Jong TD, Sellam J, Agca R, Vosslamber S, Witte BI, Tsang-A-Sjoe M, Mantel E, Bijlsma JW, Voskuyl AE, Nurmohamed MT, Verweij CL, Mariette X. de Jong TD, et al. Among authors: vosslamber s. Joint Bone Spine. 2018 Mar;85(2):219-226. doi: 10.1016/j.jbspin.2017.02.015. Epub 2017 Mar 28. Joint Bone Spine. 2018. PMID: 28363827

2

Pharmacological induction of interferon type I activity following treatment with rituximab determines clinical response in rheumatoid arthritis.

Vosslamber S, Raterman HG, van der Pouw Kraan TC, Schreurs MW, von Blomberg BM, Nurmohamed MT, Lems WF, Dijkmans BA, Voskuyl AE, Verweij CL. Vosslamber S, et al. Ann Rheum Dis. 2011 Jun;70(6):1153-9. doi: 10.1136/ard.2010.147199. Epub 2011 Mar 27. Ann Rheum Dis. 2011. PMID: 21444302 Clinical Trial.

3

The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients.

Raterman HG, Vosslamber S, de Ridder S, Nurmohamed MT, Lems WF, Boers M, van de Wiel M, Dijkmans BA, Verweij CL, Voskuyl AE. Raterman HG, et al. Among authors: vosslamber s. Arthritis Res Ther. 2012 Apr 27;14(2):R95. doi: 10.1186/ar3819. Arthritis Res Ther. 2012. PMID: 22540992 Free PMC article.

4

Effect of prednisone on type I interferon signature in rheumatoid arthritis: consequences for response prediction to rituximab.

de Jong TD, Vosslamber S, Blits M, Wolbink G, Nurmohamed MT, van der Laken CJ, Jansen G, Voskuyl AE, Verweij CL. de Jong TD, et al. Among authors: vosslamber s. Arthritis Res Ther. 2015 Mar 23;17(1):78. doi: 10.1186/s13075-015-0564-y. Arthritis Res Ther. 2015. PMID: 25889713 Free PMC article.

5

Type I interferon response gene expression in established rheumatoid arthritis is not associated with clinical parameters.

de Jong TD, Blits M, de Ridder S, Vosslamber S, Wolbink G, Nurmohamed MT, Verweij CL. de Jong TD, et al. Among authors: vosslamber s. Arthritis Res Ther. 2016 Dec 12;18(1):290. doi: 10.1186/s13075-016-1191-y. Arthritis Res Ther. 2016. PMID: 27955694 Free PMC article.

6

Pharmacogenomics of IFN-beta in multiple sclerosis: towards a personalized medicine approach.

Vosslamber S, van Baarsen LG, Verweij CL. Vosslamber S, et al. Pharmacogenomics. 2009 Jan;10(1):97-108. doi: 10.2217/14622416.10.1.97. Pharmacogenomics. 2009. PMID: 19102719 Review.

7

New insight in the mechanism of action of rituximab: the interferon signature towards personalized medicine.

Verweij CL, Vosslamber S. Verweij CL, et al. Among authors: vosslamber s. Discov Med. 2011 Sep;12(64):229-36. Discov Med. 2011. PMID: 21955850 Free article. Review.

8

Relevance of the type I interferon signature in multiple sclerosis towards a personalized medicine approach for interferon-beta therapy.

Verweij CL, Vosslamber S. Verweij CL, et al. Among authors: vosslamber s. Discov Med. 2013 Jan;15(80):51-60. Discov Med. 2013. PMID: 23375014 Free article. Review.

9

The type I IFN signature as a biomarker of preclinical rheumatoid arthritis.

Lübbers J, Brink M, van de Stadt LA, Vosslamber S, Wesseling JG, van Schaardenburg D, Rantapää-Dahlqvist S, Verweij CL. Lübbers J, et al. Among authors: vosslamber s. Ann Rheum Dis. 2013 May;72(5):776-80. doi: 10.1136/annrheumdis-2012-202753. Epub 2013 Feb 23. Ann Rheum Dis. 2013. PMID: 23434571

10

Methotrexate normalizes up-regulated folate pathway genes in rheumatoid arthritis.

Blits M, Jansen G, Assaraf YG, van de Wiel MA, Lems WF, Nurmohamed MT, van Schaardenburg D, Voskuyl AE, Wolbink GJ, Vosslamber S, Verweij CL. Blits M, et al. Among authors: vosslamber s. Arthritis Rheum. 2013 Nov;65(11):2791-802. doi: 10.1002/art.38094. Arthritis Rheum. 2013. PMID: 23897011 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

25 results

Search Page